https://www.selleckchem.com/products/lmk-235.html
Achievement of sinus rhythm (SR) is an important goal in rheumatic atrial fibrillation (AF). Studies in rheumatic AF have often used amiodarone for rhythm control. Flecainide has not been studied in these patients due to concerns of underlying structural heart disease. Pharmacological cardioversion by oral single loading dose (SLD) of Flecainide (4mg/kg, ≤300mg) was tested in 50 patients with rheumatic AF (MVA 1.51±0.19mm , age 46.2±10.28yrs, AF duration 3.10±1.7yrs, LA size 44.42±7.48mm). Non-converters underwent DC cardioversion (DCC)
Like
Comment
Share
